EP3059227A4 - SALT OF HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR CRYSTAL THEREOF, PHARMACEUTICAL COMPOSITION AND INHIBITOR OF FLT3 - Google Patents

SALT OF HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR CRYSTAL THEREOF, PHARMACEUTICAL COMPOSITION AND INHIBITOR OF FLT3

Info

Publication number: EP3059227A4
Authority: EP; European Patent Office
Prior art keywords: flt3; inhibitor; salt; crystal; pharmaceutical composition
Prior art date: 2013-10-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14854750.8A

Other languages

German (de)

French (fr)

Other versions

EP3059227A1 (en

EP3059227B1 (en

Inventor

Shinsuke Mizumoto

Takuya Matsumoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fujifilm Corp

Original Assignee

Fujifilm Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-16

Filing date

2014-10-15

Publication date

2016-09-07

2014-10-15 Application filed by Fujifilm Corp filed Critical Fujifilm Corp

2014-10-15 Priority to PL14854750T priority Critical patent/PL3059227T3/en

2016-08-24 Publication of EP3059227A1 publication Critical patent/EP3059227A1/en

2016-09-07 Publication of EP3059227A4 publication Critical patent/EP3059227A4/en

2019-06-26 Application granted granted Critical

2019-06-26 Publication of EP3059227B1 publication Critical patent/EP3059227B1/en

Status Active legal-status Critical Current

2034-10-15 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP14854750.8A 2013-10-16 2014-10-15 Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor Active EP3059227B1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
PL14854750T PL3059227T3 (en)	2013-10-16	2014-10-15	Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2013215755		2013-10-16
PCT/JP2014/077368 WO2015056683A1 (en)	2013-10-16	2014-10-15	Nitrogen-containing heterocyclic compound salt or crystal thereof, pharmaceutical composition, and flt3 inhibitor

Publications (3)

Publication Number	Publication Date
EP3059227A1 EP3059227A1 (en)	2016-08-24
EP3059227A4 true EP3059227A4 (en)	2016-09-07
EP3059227B1 EP3059227B1 (en)	2019-06-26

Family

ID=52828126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14854750.8A Active EP3059227B1 (en)	2013-10-16	2014-10-15	Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor

Country Status (14)

Country	Link
US (1)	US9701644B2 (en)
EP (1)	EP3059227B1 (en)
JP (1)	JP5887028B2 (en)
KR (1)	KR101744033B1 (en)
CN (1)	CN105683167B (en)
AU (1)	AU2014335312B9 (en)
BR (1)	BR112016008080B1 (en)
CA (1)	CA2927079C (en)
DK (1)	DK3059227T3 (en)
ES (1)	ES2738573T3 (en)
HK (1)	HK1219946A1 (en)
PL (1)	PL3059227T3 (en)
RU (1)	RU2641106C2 (en)
WO (1)	WO2015056683A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6257782B2 (en) *	2014-08-22	2018-01-10	富士フイルム株式会社	Pharmaceutical composition for treating FLT3 mutation positive cancer, mutant FLT3 inhibitor and application thereof
US11286670B2 (en)	2015-02-06	2022-03-29	Roofguard Manufacturing, Llc	Roof drain cover
JP6412471B2 (en) *	2015-07-15	2018-10-24	富士フイルム株式会社	Process for producing nitrogen-containing heterocyclic compound and intermediate thereof
TW202027749A (en)	2018-10-12	2020-08-01	日商富士軟片股份有限公司	Antitumor agent for acute myeloid leukemia
WO2020090971A1 (en) *	2018-10-31	2020-05-07	富士フイルム株式会社	Tablet containing antitumor agent
EP3875088A4 (en) *	2018-10-31	2021-12-29	FUJIFILM Corporation	Package for medical composition containing anti-tumor agent
EP3875091A4 (en) *	2018-10-31	2021-12-29	FUJIFILM Corporation	Pharmaceutical composition containing antitumor agent
WO2020090968A1 (en)	2018-10-31	2020-05-07	富士フイルム株式会社	Granule containing anti-tumor agent
TW202045174A (en)	2019-02-28	2020-12-16	日商富士軟片股份有限公司	Combinational medication
JP2022526713A (en)	2019-03-21	2022-05-26	オンクセオ	Dbait molecule in combination with a kinase inhibitor for the treatment of cancer
CN114761006A (en)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2023027966A1 (en)	2021-08-24	2023-03-02	Biomea Fusion, Inc.	Pyrazine compounds as irreversible inhibitors of flt3
WO2023129667A1 (en)	2021-12-30	2023-07-06	Biomea Fusion, Inc.	Pyrazine compounds as inhibitors of flt3
WO2023225005A1 (en)	2022-05-17	2023-11-23	Biomea Fusion, Inc.	Flt3 combination therapy for cancer and compositions therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030171359A1 (en) *	2001-10-17	2003-09-11	Boehringer Ingelheim Pharma Kg	Pyrimidine derivatives
WO2006133426A2 (en) *	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2013157540A1 (en) *	2012-04-17	2013-10-24	富士フイルム株式会社	Nitrogen-containing heterocyclic compound or salt thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8928839D0 (en)	1989-12-21	1990-02-28	Beecham Group Plc	Novel compounds
US5936399A (en) *	1997-09-16	1999-08-10	Mitutoyo Corporation	Inductive position transducer having a multi-tap receiver winding
CN101282945A (en) *	2005-06-08	2008-10-08	里格尔药品股份有限公司	Compositions and methods for inhibition of the JAK pathway
US20060281755A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US8071768B2 (en) *	2005-06-10	2011-12-06	Janssen Pharmaceutica, N.V.	Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) *	2005-06-10	2010-11-02	Janssen Pharmaceutica Nv	Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
EP3173084B1 (en)	2005-11-11	2019-10-23	Boehringer Ingelheim International GmbH	Quinazoline derivatives for the treatment of cancer diseases
US7820657B2 (en)	2006-03-17	2010-10-26	Ambit Biosciences Corporation	Imidazolothiazole compounds for the treatment of disease
EP2022785A1 (en) *	2007-06-20	2009-02-11	Bayer Schering Pharma Aktiengesellschaft	Alkynylpyrimidines as Tie2 kinase inhibitors
CN101779250B (en) *	2007-06-21	2014-01-08	桑迪士克科技股份有限公司	Intelligent control of program pulse duration
PL2252597T3 (en)	2008-02-01	2014-09-30	Akinion Pharmaceuticals Ab	Pyrazine derivatives and their use as protein kinase inhibitors
AU2009248923B2 (en)	2008-05-21	2015-01-29	Takeda Pharmaceutical Company Limited	Phosphorous derivatives as kinase inhibitors
US9908884B2 (en) *	2009-05-05	2018-03-06	Dana-Farber Cancer Institute, Inc.	EGFR inhibitors and methods of treating disorders
US9290485B2 (en) *	2010-08-04	2016-03-22	Novartis Ag	N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
JP5956999B2 (en)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	Heteroaryl compounds and uses thereof
ES2665013T3 (en)	2010-11-10	2018-04-24	Celgene Car Llc	EGFR selective mutant inhibitors and uses thereof
US8703767B2 (en)	2011-04-01	2014-04-22	University Of Utah Research Foundation	Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
WO2012150952A1 (en)	2011-05-04	2012-11-08	Forma Tm, Llc	Novel compounds and compositions for the inhibition of nampt

2014
- 2014-10-15 CA CA2927079A patent/CA2927079C/en active Active
- 2014-10-15 KR KR1020167008954A patent/KR101744033B1/en active IP Right Grant
- 2014-10-15 ES ES14854750T patent/ES2738573T3/en active Active
- 2014-10-15 PL PL14854750T patent/PL3059227T3/en unknown
- 2014-10-15 AU AU2014335312A patent/AU2014335312B9/en active Active
- 2014-10-15 EP EP14854750.8A patent/EP3059227B1/en active Active
- 2014-10-15 DK DK14854750.8T patent/DK3059227T3/en active
- 2014-10-15 RU RU2016114540A patent/RU2641106C2/en active
- 2014-10-15 WO PCT/JP2014/077368 patent/WO2015056683A1/en active Application Filing
- 2014-10-15 JP JP2015540773A patent/JP5887028B2/en active Active
- 2014-10-15 BR BR112016008080-7A patent/BR112016008080B1/en active IP Right Grant
- 2014-10-15 CN CN201480056478.4A patent/CN105683167B/en active Active
2016
- 2016-04-15 US US15/130,168 patent/US9701644B2/en active Active
- 2016-07-06 HK HK16107873.9A patent/HK1219946A1/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030171359A1 (en) *	2001-10-17	2003-09-11	Boehringer Ingelheim Pharma Kg	Pyrimidine derivatives
WO2006133426A2 (en) *	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2013157540A1 (en) *	2012-04-17	2013-10-24	富士フイルム株式会社	Nitrogen-containing heterocyclic compound or salt thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015056683A1 *

Also Published As

Publication number	Publication date
BR112016008080B1 (en)	2021-02-23
WO2015056683A1 (en)	2015-04-23
ES2738573T3 (en)	2020-01-23
CA2927079C (en)	2017-05-23
AU2014335312B2 (en)	2017-01-05
RU2016114540A (en)	2017-11-21
EP3059227A1 (en)	2016-08-24
HK1219946A1 (en)	2017-04-21
US9701644B2 (en)	2017-07-11
JP5887028B2 (en)	2016-03-16
CN105683167A (en)	2016-06-15
AU2014335312B9 (en)	2017-05-25
CN105683167B (en)	2018-10-23
AU2014335312A1 (en)	2016-05-05
RU2641106C2 (en)	2018-01-16
KR20160049009A (en)	2016-05-04
US20160229812A1 (en)	2016-08-11
EP3059227B1 (en)	2019-06-26
JPWO2015056683A1 (en)	2017-03-09
CA2927079A1 (en)	2015-04-23
DK3059227T3 (en)	2019-08-26
BR112016008080A8 (en)	2020-03-17
KR101744033B1 (en)	2017-06-07
PL3059227T3 (en)	2019-11-29

Publication	Publication Date	Title
EP3059227A4 (en)	2016-09-07	SALT OF HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR CRYSTAL THEREOF, PHARMACEUTICAL COMPOSITION AND INHIBITOR OF FLT3
EP2840080A4 (en)	2015-09-23	HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR SALT THEREOF
EP2944637A4 (en)	2015-11-18	HETEROCYCLIC COMPOUND CONTAINING NITROGEN OR SALT THEREOF
ECSP16076566A (en)	2017-03-31	FUSED BICYCLIC HETEROARYL OR ARYL COMPOUNDS AND THEIR APPLICATION TO IRAK4 INHIBITORS
EP2921480A4 (en)	2016-04-13	HETEROCYCLIC COMPOUND CONTAINING NITROGEN
PE20170331A1 (en)	2017-04-28	QUINOLINE DERIVATIVES AS SMO INHIBITORS
EA201300200A1 (en)	2013-06-28	N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
EA201690848A1 (en)	2016-08-31	Derivatives of Bicyclic Pyridyl with Condensed Rings as FGFR4 Inhibitors
EP2903613A4 (en)	2016-04-20	ACTIVITY INHIBITORS OF IRAQ4
EP2821402A4 (en)	2015-08-19	AROMATIC HETEROCYCLIC COMPOUND CONTAINING NITROGEN
EP2687507A4 (en)	2014-12-03	CONDENSED HETEROCYCLIC COMPOUND CONTAINING NITROGEN
BR112015021983A8 (en)	2019-12-03	heterocyclic compounds, compositions and uses thereof
LT3555070T (en)	2023-09-11	Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
EA201690598A1 (en)	2016-10-31	AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS
EA201590661A1 (en)	2015-09-30	AZACHINASOLINE INHIBITORS OF ATYPICAL PROTEINKINASE C
EA201491936A1 (en)	2015-03-31	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
EP2881384A4 (en)	2015-12-23	HETEROCYCLIC COMPOUND CONTAINING PARTIALLY SATURATED NITROGEN
EP3373932A4 (en)	2019-08-07	CRYSTALLINE FORM OF SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
CR20140494A (en)	2015-03-13	DGAT1 INHIBITORS OF ETER CYCLING HEAD BRIDGE
UA109290C2 (en)	2015-08-10	Common Crystals and Salts of CCR3 Inhibitors
EP2927214A4 (en)	2016-07-06	HETEROCYCLIC COMPOUND CONTAINING NITROGEN
EA201500821A1 (en)	2016-03-31	Derivatives of 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purines, their use as pharmaceuticals and pharmaceutical compounds
EP2871185A4 (en)	2016-04-20	HETEROCYCLIC COMPOUND CONTAINING NITROGEN AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME
EP2976338A4 (en)	2016-08-31	N- (2-CYANO-HETEROCYCLYL) PYRAZOLO-PYRIDONES AS INHIBITORS OF JANUS KINASE
EA201692270A1 (en)	2017-03-31	DERIVATIVES OF NAFTYRIDINDIONE

Legal Events

Date	Code	Title	Description
2016-07-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-08-24	17P	Request for examination filed	Effective date: 20160415
2016-08-24	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-08-24	AX	Request for extension of the european patent	Extension state: BA ME
2016-09-07	A4	Supplementary search report drawn up and despatched	Effective date: 20160809
2016-09-07	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 239/48 20060101AFI20160803BHEP Ipc: A61P 43/00 20060101ALI20160803BHEP Ipc: A61K 31/505 20060101ALI20160803BHEP Ipc: A61P 35/02 20060101ALI20160803BHEP
2017-01-25	DAX	Request for extension of the european patent (deleted)
2018-04-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-05-23	17Q	First examination report despatched	Effective date: 20180423
2018-11-26	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-11-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-12-26	INTG	Intention to grant announced	Effective date: 20181127
2019-04-09	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2019-05-22	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: FUJIFILM CORPORATION
2019-05-24	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2019-05-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2019-06-26	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-06-26	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2019-06-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2019-07-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1148121 Country of ref document: AT Kind code of ref document: T Effective date: 20190715
2019-07-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014049239 Country of ref document: DE
2019-07-24	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2019-07-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH, CH
2019-08-26	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20190822
2019-08-28	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2019-09-10	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2019-10-28	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20190626
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2019-11-11	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190926 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190927
2020-01-23	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2738573 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200123
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191028 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191026 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2020-06-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014049239 Country of ref document: DE
2020-06-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)
2020-07-03	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2020-07-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2020-07-30	PG2D	Information on lapse in contracting state deleted	Ref country code: IS
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191015
2020-08-05	26N	No opposition filed	Effective date: 20200603
2020-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20141015 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190626
2022-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1148121 Country of ref document: AT Kind code of ref document: T Effective date: 20190626
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230515
2024-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20240910 Year of fee payment: 11
2024-10-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240829 Year of fee payment: 11
2024-10-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20240917 Year of fee payment: 11
2024-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240909 Year of fee payment: 11
2024-10-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20240917 Year of fee payment: 11
2024-10-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20240916 Year of fee payment: 11
2024-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20240910 Year of fee payment: 11 Ref country code: SE Payment date: 20240910 Year of fee payment: 11
2024-11-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20240924 Year of fee payment: 11
2025-01-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240828 Year of fee payment: 11
2025-01-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NO Payment date: 20241009 Year of fee payment: 11
2025-01-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20241011 Year of fee payment: 11
2025-01-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20241015 Year of fee payment: 11
2025-01-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20240925 Year of fee payment: 11
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20241101 Year of fee payment: 11
2025-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20241101 Year of fee payment: 11